Imperial College's London's vaccine candidate moves on to next phase
|After receiving successful results during the initial phase with 15 volunteers, Imperial College London's COVID-19 vaccine candidate is ready for the next phase, Imperial College London announced in a press release.
"In this next phase of the trial, 105 participants aged 18-75 will be randomised to receive their first shot of one of three doses of the vaccine at a west London facility, followed by a booster four weeks later," the statement read. "The three arms of the study are blinded, so neither participant nor clinical staff will know which dose they have received."
Market reaction
This headline doesn't seem to be having a significant impact on market sentiment. As of writing, the UK's FTSE 100 Index was up 0.52% on the day at 6,282.
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers.